What We Offer?


  • Peer-Reviewed Research: Cutting-edge studies, clinical trials, and systematic reviews spanning diabetes, cardiology, nephrology, and intersecting technologies.
  • Innovative Technology Highlights: Original research and commentary on digital health, artificial intelligence, remote patient monitoring, and modern diagnostics that are shaping the future of holistic care.
  • Expert Perspectives: Opinion pieces, consensus guidelines, and case discussions from leading clinicians and researchers working at the forefront of cardio-diabetes-renal medicine.
  • Global Community: A vibrant, interdisciplinary space for collaboration, knowledge sharing, and professional development.
 

Why Diabzen?

With the rapid evolution of medical science and digital health, Diabzen curates the latest advances in one convenient, high-impact forum. We invite physicians, scientists, allied health professionals, and industry leaders to join our community—contributing to an evidence-based, patient-centered future and elevating standards of care for millions worldwide.

Submit. Discover. Innovate.

Whether you are looking to share new research, stay updated with clinical breakthroughs, or engage with a global network of experts, Diabzen is your gateway to progress in cardio-diabetes-renal medicine and beyond.
Explore the latest issue, submit your work, or learn more about our mission. Together, let’s shape the future of integrated healthcare.
Diabzen: Advancing Care at the Core.

Current Issue

Vol. 3 No. 4 (2025): FIB-4 ≥1.3 is correlated with increased DKD risk in T2D, but SGLT2i therapy that lowers FIB-4 attenuates this
					View Vol. 3 No. 4 (2025): FIB-4 ≥1.3 is correlated with increased DKD risk in T2D, but SGLT2i therapy that lowers FIB-4 attenuates this
Published: 2025-12-15
View All Issues